Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: The Roman experience

Neurological Sciences

Volumn 26, Issue SUPPL. 4, 2005, Pages

  Pozzilli, Carlo ^a   Prosperini, L ^a   Sbardella, E ^a   De Giglio, L ^a   Onesti, E ^a   Tomassini, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Disability progression; Interferon beta; MRI; Multiple sclerosis; Predictors of response; Relapse rate

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; MITOXANTRONE;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PHYSICAL DISABILITY; POSTMARKETING SURVEILLANCE; RATING SCALE; RELAPSE; RETROSPECTIVE STUDY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; COHORT STUDIES; DISABILITY EVALUATION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PRODUCT SURVEILLANCE, POSTMARKETING; RECURRENCE; ROME; TREATMENT OUTCOME;

EID: 30644462726     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-005-0510-x     Document Type: Article

References (20)

1. The IFN beta Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN BETA Multiple Sclerosis Study Group. Neurology 43:655-661
2. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 352:1498-1504
4. Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/ MRI Study Group and the IFN BETA Multiple Sclerosis Study Group. Neurology 43:662-667
5. Simon JH, Jacobs LD, Campion M et al (1998) Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative research Group. Ann Neurol 43:79-87
6. Li DK, Paty DW (1999) Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis. Ann Neurol 42:197-206
7. Vermersch P, de Seze J, Stojkovic T et al (2002) G-SEP (Groupe Septentrional d'Etudes et de Recherches sur la SEP). Interferon beta-1a (Avonex) treatment in multiple sclerosis: Similarity of effect on progression of disability in patients with mild and moderate disability. J Neurol 249:184-187
8. Waubant E, Vukusic S, Gignoux L et al (2003) Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61:184-189
9. Trojano M, Liguori M, Paolicelli D et al (2003) Interferon beta in relapsing-remitting multiple sclerosis: An independent post-marketing study in southern Italy. Mult Scler 9:451-457
10. Milanese C, La Mantia L, Palumbo R et al (2003) A postmarketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74:1689-1692
11. Onesti E, Bagnato F, Tomassini V et al (2003) Interferon beta treatment of MS in the daily clinical setting: A 3-year post-marketing study. Neurol Sci 24:340-345
12. Tomassini V, Paolillo A, Russo P et al (2005) Predictors of long-term clinical response to Interferon beta therapy in relapsing multiple sclerosis. J Neurol (in press)
13. Pozzilli C, Bastianello S, Koudriavtseva T et al (1996) Magnetic resonance imaging changes with recombinant human interferon beta-1a: A short term study in relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 61:251-258
14. Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis. Ann Neurol 13:227-231
15. PRISMS Study Groups and the UBC MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology 56:1628-1636
16. Stone LA, Frank JA, Albert PS et al (1997) Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 49:862-869
17. Koudriavtseva T, Pozzilli C, Fiorelli M et al (1998) Determinants of Gd-enhanced MRI response to IFN beta-1a treatment in relapsing-remitting multiple sclerosis. Mult Scler 4:403-407
18. Sormani MP, Bruzzi P, Beckmann K et al (2005) The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis. J Neurol 18:1432-1459
19. Rudick RA, Lee JC, Simon J et al (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56:548-555
20. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon beta-1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon beta-1a in secondary progressive MS: Clinical results. Neurology 56:1496-1504